Cargando…
Treating the patient and not just the cancer: therapeutic burden in prostate cancer
BACKGROUND: Prostate cancer (PC) is a leading cause of death in older men. Androgen deprivation therapy (ADT) is considered the standard-of-care for men with locally advanced disease. However, continuous androgen ablation is associated with acute and long-term adverse effects and most patients will...
Autores principales: | Spratt, Daniel E., Shore, Neal, Sartor, Oliver, Rathkopf, Dana, Olivier, Kara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384628/ https://www.ncbi.nlm.nih.gov/pubmed/33603236 http://dx.doi.org/10.1038/s41391-021-00328-1 |
Ejemplares similares
-
Correction: Treating the patient and not just the cancer: therapeutic burden in prostate cancer
por: Spratt, Daniel E., et al.
Publicado: (2021) -
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
por: Sartor, A Oliver
Publicado: (2011) -
Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America
por: Joshua, Anthony M., et al.
Publicado: (2015) -
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020) -
Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)